# Bluestem Capital

> Bluestem Capital is a VC fund in Sioux Falls backing Health Care and Medical. See 31 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Sioux Falls, United States
- Total investments: 31
- Last investment: Oct 2024
- Lead investor: 45%
- Last fund: Oct 2018
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/bluestem-capital-co/
- Website: http://www.bluestemcapital.com

Bluestem Capital is a VC fund in Sioux Falls focused on Health Care and Medical. Bluestem Capital provided herein is for informational and convenience purposes only. The information provided on this website does not constitute an offer to buy or sell any securities or provide any form of investment advice.

## Contacts

5 contacts available for Bluestem Capital. Shizune tracks 3 team members at Bluestem Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bluestem-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 29% |
| Medical | 6 | 19% |
| Medical Device | 5 | 16% |
| Software | 4 | 13% |
| Pharmaceutical | 4 | 13% |

39 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 8 | 26% |
| Series A | 7 | 23% |
| Funding Round | 6 | 19% |
| Series C | 3 | 10% |
| Venture - Series Unknown | 2 | 6% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 18 | 58% |
| Israel | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Tyler J. Stowater | Partner and Vice President | 3 | https://shizune.co/investors/profile/tyler-j-stowater |
| Sandy Horst | Partner & CFO | 0 | https://shizune.co/investors/profile/sandy-horst |
| Steve Kirby | Founder & Partner | 2 | https://shizune.co/investors/profile/steve-kirby |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Orasis Pharmaceuticals | Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, andeasy-to-use. | $68M | Series D | Oct 08, 2024 |  |
| Lentechs | Lentechs is a medical device company that develops a novel soft bifocal contact lens. The company is headquartered in Columbus, Ohio. | $6M | Venture - Series Unknown | Oct 24, 2023 |  |
| Virtual Incision | Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients. It has develops the MIRA® (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device,focusing first on colon resection, with follow-on specialty robots for additional potential applications. | $30M | Series C | Sep 19, 2023 |  |
| Neurolens | Neurolens are prescription lenses that add a contoured prism to bring the eyes into alignment, relieving the headaches, neck or shoulder pain, and eyestrain that many people experience when using digital devices, reading, or doing detailed work. The company was founded in 2012 and is headquartered in Costa Mesa, California. | $67.6M | Venture - Series Unknown | Sep 08, 2022 |  |
| Virtual Incision | Virtual Incision is reimagining robotic support for minimally invasive (MIS) procedures with simple innovations offering mobility, flexibility, and accessibility to provide MIS options to more patients. It has develops the MIRA® (Miniaturized In vivo Robotic Assistant) Platform, a first-of-its-kind miniaturized surgical robotic support device,focusing first on colon resection, with follow-on specialty robots for additional potential applications. | $46M | Series C | Nov 30, 2021 |  |
| Zerigo Health | Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions.Clarify Medicalindicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction. | $43M | Series B | Oct 21, 2021 |  |
| Sydnexis | Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia, a major global unmet medical need. Sydnexis manufactures pharmaceutical product for ophthalmic disorder or condition. | $45M | Series B | Aug 10, 2021 |  |
| Sydnexis | Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia, a major global unmet medical need. Sydnexis manufactures pharmaceutical product for ophthalmic disorder or condition. | $45M | Series B | Aug 10, 2021 |  |
| Orasis Pharmaceuticals | Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, andeasy-to-use. | $30M | Series C | Sep 10, 2020 |  |
| TearClear | TearClear is a pharmaceutical company that specializes in providing a class platform of drugs enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface. The company was founded in 2015 and headquartered in California, United States. | $22M | Series B | Aug 11, 2020 |  |

10 of 31 investments shown.

## Co-investors
- [Visionary Venture Fund](https://shizune.co/investors/profile/visionary-venture-fund) — VC Fund, 7 deals together
- [PrairieGold Venture Partners](https://shizune.co/investors/profile/prairiegold-venture-partners) — VC Fund, 5 deals together
- [Longitude Capital](https://shizune.co/investors/profile/longitude-capital) — VC Fund, 4 deals together
- [7wire Ventures](https://shizune.co/investors/profile/7wire-ventures) — VC Fund, 3 deals together
- [Edgewater Funds](https://shizune.co/investors/profile/edgewater-private-equity-fund) — VC Fund, 3 deals together
- [Arboretum Ventures](https://shizune.co/investors/profile/arboretum-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Bluestem Capital invest in?

Bluestem Capital invests primarily in Health Care, Medical and Medical Device startups, most often at Series B and Series A stage. Most of the 31 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Bluestem Capital?

Public channels for Bluestem Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Bluestem Capital?

The team at Bluestem Capital includes Tyler J. Stowater (Partner and Vice President), Sandy Horst (Partner & CFO) and Steve Kirby (Founder & Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co